Also listed on Pharmedium Services, LLC, an earlier holder on the record. The recorded assignments below show how it moved.
Term ends May 19, 2028 · High confidence
20-year base term ends May 19, 2028
Held by Hikma Pharmaceuticals USA Inc.
Filed Mar 2, 2011 as application 13/038,937 · Granted Feb 26, 2013
Base term, 20 years from filing
Today
2008
2028
Clock starts
May 19, 2008
May 19, 2008
Term ends
May 19, 2028
May 19, 2028
Granted
Feb 26, 2013
Feb 26, 2013
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,918,830, to May 19, 2028. The term already ends on or before that date, so the cap shortened nothing.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
13
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 19, 2008, when application 12/123,301, the earliest non-provisional in its chain, was filed (this one was filed Mar 2, 2011) | May 19, 2028 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,918,830) | resolves to May 19, 2028, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | May 19, 2028 | High confidence |
This family
| US D588,200 | Term ended Mar 2023 | Mar 2023 |
| US 7,918,830 | In force May 2028 | May 2028 |
| Application PCT/US2008/083171 | PCT application no patent term | no patent term |
| US D595,361 | Term ended Jun 2023 | Jun 2023 |
| US D602,534 | Term ended Oct 2023 | Oct 2023 |
| US D593,613 | Term ended Jun 2023 | Jun 2023 |
| US D605,228 | Term ended Dec 2023 | Dec 2023 |
| US D614,703 | Term ended Apr 2024 | Apr 2024 |
8 of 13 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 14, 2011 Reel 25949, frame 960 | Langan, Amy Elizabeth; Kruzynski, Richard John; Kollar, John Anton; Miyake, Patricia Lynn; Kruk, Monique Lasayre; Wagner, Mark Francis | Pharmedium Services, LLC | Assignment of Assignor's Interest |
| Dec 26, 2012 Reel 29539, frame 528 | Pharmedium Services, LLC | Bank of Montreal | Security Agreement |
| Feb 20, 2014 Reel 32301, frame 828 | Pharmedium Services, LLC | Jpmorgan Chase Bank, N.a. | Notice and Confirmation of Grant of Security Interest in Patents-First Lien |
| Feb 20, 2014 Reel 32302, frame 275 | Pharmedium Services, LLC | Credit Suisse AG | Notice and Confirmation of Grant of Security Interest in Patents - Second Lien |
| Aug 26, 2015 Reel 36477, frame 200 | Bank of Montreal | Pharmedium Services, LLC | Termination and Release of Security Interest in Patents |
| Nov 11, 2015 Reel 37097, frame 493 | Credit Suisse AG | Pharmedium Services, LLC | Termination and Release of Security Interest in Patent Rights - Second Lien |
| Nov 11, 2015 Reel 37097, frame 514 | Jpmorgan Chase Bank, N.a. | Pharmedium Services, LLC | Termination and Release of Security Interest in Patent Rights - First Lien |
| Aug 31, 2020 Reel 53646, frame 281 | Pharmedium Service, LLC | Runway Advisors, LLC | Assignment of Assignor's Interest |
| Feb 16, 2021 Reel 55270, frame 335 | Runway Advisors, LLC | Hikma Pharmaceuticals USA Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
May 2028
Term ends May 19, 2028. No further fees fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 7,918,830, ends no earlier than this term, so it caps nothing.
Citations
32
later US patents cite this one
That is top 25% of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.